Overview
AirSculpt Q3 revenue declines 17.8% yr/yr, missing analyst expectations
Adjusted EBITDA for Q3 misses analyst estimates, declining to $3.0 mln
Company updates 2025 revenue and EBITDA guidance to lower bound of previous range
Outlook
Company updates 2025 revenue guidance to $153 mln, down from $160-$170 mln
AirSculpt expects 2025 adjusted EBITDA to be approximately $16 mln
Improvement in same store sales trends observed entering Q4
Company sees broader market opportunity due to structural shift in aesthetics space
Result Drivers
GLP-1 OPPORTUNITIES - Co sees broader market opportunity in aesthetics space due to GLP-1 use
DEBT REDUCTION - Co reduced debt by $18 mln and delivered positive cash flow YTD
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Miss | $35 mln | $39.50 mln (4 Analysts) |
Q3 Net Income | -$9.50 mln | ||
Q3 Adjusted EBITDA | Miss | $3 mln | $3.81 mln (4 Analysts) |
Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the healthcare facilities & services peer group is "buy."
Wall Street's median 12-month price target for AirSculpt Technologies Inc is $6.00, about 74.8% below its November 6 closing price of $10.49
Press Release: ID:nGNX8jNLv
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)